What have we learned from gene expression profiles in Huntington's disease?

被引:109
|
作者
Seredenina, Tamara [1 ]
Luthi-Carter, Ruth [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Lab Funct Neurogen, CH-1015 Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
Polyglutamine disease; huntingtin; Transcriptomic profiling; Striatum; Cortex; Muscle; Blood; Microarray; Biomarker; HISTONE DEACETYLASE INHIBITORS; NEURONAL INTRANUCLEAR INCLUSIONS; CRE-MEDIATED TRANSCRIPTION; ADENOSINE A(2A) RECEPTORS; TRANSGENIC MOUSE MODELS; CELL-CELL INTERACTIONS; MUTANT-HUNTINGTIN; SYNAPTIC PLASTICITY; BINDING-PROTEIN; MESSENGER-RNA;
D O I
10.1016/j.nbd.2011.07.001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The availability of many high-quality genome-wide expression datasets has provided an exciting and unique opportunity to better understand the molecular etiology of Huntington's disease. Combining this knowledge with other aspects of huntingtin biology and disease modification screens is yielding important new insights into disease-mitigating therapeutic strategies. Having followed this line of inquiry for some time, we note that there have been a number of surprises regarding the subsequently confirmed relationships between gene expression and disease etiology. Moreover, the complexity and sheer number of proposed mechanisms by which huntingtin can perturb gene expression continues to expand. Nonetheless, ongoing efforts to enthusiastically and critically evaluate the relationships between HD pathobiology and gene expression promise to deliver accurate predictions as to which therapeutic strategies will be most effective. An exciting new arm of this research also demonstrates the power of pharmacogenomics to detect (and rule out) important neuroprotective gene expression effects. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:83 / 98
页数:16
相关论文
共 50 条
  • [31] What have we learned from past failures of investigational drugs for Alzheimer's disease?
    Imbimbo, Bruno P.
    Watling, Mark
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (12) : 1175 - 1182
  • [32] What Have We Learned From Antibiotics?
    Smith, James Leif
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (08) : 1183 - 1183
  • [33] What We Have Learned from Helioseismology
    Michael J. Thompson
    Astrophysics and Space Science, 1998, 261 : 23 - 34
  • [34] What we have learned from helioseismology
    Thompson, MJ
    ASTROPHYSICS AND SPACE SCIENCE, 1998, 261 (1-4) : 23 - 34
  • [35] What have we learned from OpenReview?
    Wang, Gang
    Peng, Qi
    Zhang, Yanfeng
    Zhang, Mingyang
    WORLD WIDE WEB-INTERNET AND WEB INFORMATION SYSTEMS, 2023, 26 (02): : 683 - 708
  • [36] WHAT WE HAVE LEARNED FROM CHERNOBYL
    LUSHBAUGH, CC
    DISCHER, DP
    WESTERN JOURNAL OF MEDICINE, 1988, 148 (01): : 76 - 77
  • [37] What have we learned from SHIVA?
    Le Tourneau, Christophe
    Kurzrock, Razelle
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (12) : 719 - 720
  • [38] What have we learned from BeSt?
    Allaart, Cornelia F.
    Markusse, Iris M.
    Lems, Willem F.
    CLINICAL IMMUNOLOGY, 2018, 186 : 74 - 78
  • [39] What have we learned from the pandemic?
    Holcomb, Liz
    NURSE RESEARCHER, 2022, 30 (02) : 5 - 5
  • [40] What have we learned from nonimmobilizers?
    Eger, EI
    MOLECULAR AND BASIC MECHANISMS OF ANESTHESIA, 2002, : 58 - 60